Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15883231 | 0.87 | HSD11B1 (0.49) | HSD11B1SMN1; SMN2HDAC3HDAC1HDAC2 | |
| SCHEMBL18536749 | 0.72 | HSD11B1 (0.48) | HSD11B1ALDH1A1LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL23812236 | 0.70 | HSD11B1 (0.59) | CYP11B1CYP11B2HSD11B1ALDH1A1LMNA | |
| SCHEMBL6328945 | 0.69 | HPGD (0.60) | ALDH1A1SMN1; SMN2CYP1A2HDAC1HDAC2 | |
| SCHEMBL4109675 | 0.68 | LMNA (0.54) | ALDH1A1LMNAKDM4ESMN1; SMN2LTA4H | |
| Bromide SCHEMBL28931279 | 0.68 | MAPT (0.59) | ALDH1A1LMNAKDM4ESMN1; SMN2HDAC3 | |
| SCHEMBL162806 | 0.67 | HDAC1 (0.62) | ALDH1A1LMNAKDM4ESMN1; SMN2HDAC3 | |
| SCHEMBL23336762 | 0.67 | HSD11B1 (0.55) | HSD11B1ALDH1A1HDAC3HDAC1HDAC2 | |
| Methylamine SCHEMBL6594130 | 0.67 | ALDH1A1 (0.58) | ALDH1A1LMNASMN1; SMN2HDAC1HDAC2 | |
| SCHEMBL21606911 | 0.67 | HSD11B1 (0.65) | CYP11B1CYP11B2HSD11B1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2943494-B1 | PYRIDO- OR PYRROLO-FUSED PYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS FOR TREATING PAIN | LILLY CO ELI (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2943494-B1 | PYRIDO- OR PYRROLO-FUSED PYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS FOR TREATING PAIN | LILLY CO ELI (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2943494-A1 | PYRIDO- OR PYRROLO-FUSED PYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS FOR TREATING PAIN | Eli Lilly and Company (US) | 2015-11-18 | — | — | EP | disclosed |
| US-8969555-B2 | Bicyclic pyrimidine compounds | ELI LILLY AND COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969555-B2 | Bicyclic pyrimidine compounds | ELI LILLY AND COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969555-B2 | Bicyclic pyrimidine compounds | ELI LILLY AND COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140200231-A1 | Bicyclic Pyrimidine Compounds | ELI LILLY AND COMPANY (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140200231-A1 | Bicyclic Pyrimidine Compounds | ELI LILLY AND COMPANY (US) | 2014-07-17 | — | — | US | disclosed |
| WO-2014110000-A1 | PYRIDO- OR PYRROLO-FUSED PYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014110000-A1 | PYRIDO- OR PYRROLO-FUSED PYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 2014-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200231-A1 | Bicyclic Pyrimidine Compounds | ENPP2, HAX1, NUDT1 | CYP11B1 3597/4885CYP11B2 3059/4885HSD11B1 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.